<DOC>
	<DOCNO>NCT00708422</DOCNO>
	<brief_summary>The purpose randomize , double-masked , parallel-group , multicenter study evaluate ocular surface effect administration travoprost SofZia® preservative system Xalatan daily 12 week .</brief_summary>
	<brief_title>Effects Travatan Z Xalatan Ocular Surface Health</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>18 year age old . Diagnosis primary openangle glaucoma ( without pseudoexfoliation pigment dispersion ) ocular hypertension least one eye ( study eye ) . Use BAK ( benzalkonium chloride ) contain intraocular pressure ( IOP ) lower medication minimum one year , include latanoprost ( Xalatan® ) monotherapy least 6 month prior Visit 1 . IOP controllable stable study medication alone ( eye ) . Believed ocular surface disease ( OSD ) . Tear Breakup Time ( TBUT ) ≤ 6 second study eye . Willing able discontinue use topical ocular medication study medication BAK free artificial tear duration study . Other protocoldefined inclusion criterion may apply . Current use use within last 3 month cyclosporine ophthalmic emulsion 0.05 % ( Restasis® ) , topical ocular steroid , topical ocular nonsteroidal antiinflammatory drug . Current use punctual plug . Women childbearing potential use reliable mean birth control . Women pregnant lactating . Suspected diagnose Sjogrens 's syndrome . Current use brand artificial tear contain BAK . Use systemic medication chronic basis stable dose regimen least 30 day prior Visit 1 , anticipate change dose regimen medication course study . Intraocular conventional surgery laser surgery study eye less six month prior Visit 1 . Current use contact lens within 30 day Visit 1 . Participation investigational study within 30 day prior Visit 1 . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Ocular surface health</keyword>
	<keyword>OSDI</keyword>
	<keyword>TFBUT</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Corneal stain</keyword>
</DOC>